Freenome Inc. (FRNM) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
FRED Regime × Technicals: 39% of 52W Range • RSI-14 at 39.9 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While FRNM currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.73) and Max Pain ($13.50) forces dealer call-delta covering toward $18.38.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Freenome Inc. (FRNM) dropped -4.32% to $12.86, trading at 39% of its 52-week range ($9.95 – $17.5). Stretched risk/reward at current multiples (-3% return on capital) under elevated 10-year interest-rate pressure.
Key TakeawaysFreenome shares rose 11% today after it launched SimpleScreen Lung, a lung cancer blood test that can run with its FDA-approved colon cancer test from one blood draw. About half of people without lung cancer
– Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw – – In an independent cohort, SimpleScreen Lung showed 85% sensitivity at 50% specificity and
– Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw –– In an independent cohort, SimpleScreen Lung showed 85% sensitivity at 50% specificity and
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on FRNM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for FRNM. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Freenome Inc. (FRNM) ranks #909 by composite RQD confidence (31/100, grade E) and #313 by equity capitalization ($1.38B). Within this direct 5-issuer industry benchmark cohort, TRUP leads on earnings valuation at 68.2x trailing P/E, while ALHC leads on capital efficiency and profitability with 13.9% ROIC and — gross margin. ALHC currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with FRNM at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| FRNM
ACTIVE
Freenome Inc. | E | 31/100 | — | — | -3.4% | -4.32% | $1.38B | Benchmark Subject |
| TRUP Trupanion Inc. | C | 64/100 | 68.2x | 16.1% | 3.1% | +2.27% | $1.32B | /trup-vs-frnm → |
| CSTL Castle Biosciences Inc. | C- | 60/100 | — | 79.4% | -9.3% | +4.99% | $1.18B | /cstl-vs-frnm → |
| ALHC Alignment Healthcare Inc. | C+ | 67/100 | — | — | 13.9% | -1.47% | $1.67B | /alhc-vs-frnm → |
| LMRI Lumexa Imaging Holdings Inc. | D+ | 58/100 | — | — | — | +0.95% | $1.13B | /lmri-vs-frnm → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Freenome Inc. (FRNM) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $837.5K, operating cash flow of -$864.7K, and free cash flow of -$864.7K . On the balance sheet, FRNM closed FY2025 with $92.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $837.5K | -$864.7K | -$864.7K | $92.8M | — |
| FY2024 (FY) | 2024-12-31 | $0 | $0 | — | — | $89.9M | — |
As of 2026-11-01, Freenome Inc. (NASDAQ: FRNM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $12.86 (-4.32% 1D, market cap $1.38B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, FRNM ranks #909 in composite RQD confidence.
Within the Health Care sector (Medical Specialities), FRNM carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -3.4%. By comparison, TRUP (Trupanion Inc.) holds a C grade (64/100 RQD, P/E 68.2x, ROIC 3.1%, cap $1.32B) and CSTL (Castle Biosciences Inc.) posts a C- grade (60/100 RQD, P/E N/A, ROIC -9.3%, cap $1.18B). Among the 5-stock peer group, TRUP leads on earnings multiple (68.2x) while ALHC leads on capital efficiency (13.9% ROIC).
Per FRNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002017526), Freenome Inc. generated $0 in revenue, $837.5K in net income, and -$864.7K in free cash flow against $92.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
FRNM last traded at $12.86 (-4.32% on volume of 360,311 shares), positioning the stock -12.70% below its 50-day simple moving average ($14.73) and +2.80% above its 200-day simple moving average ($12.51). Across its 52-week range of $9.95 to $17.50, FRNM sits at the 38.5% percentile with a 14-day RSI of 39.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($11.25 to $14.47).
Why FRNM Stock dropped -4.32% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-3% return on capital) under elevated 10-year interest-rate pressure.